Unlock instant, AI-driven research and patent intelligence for your innovation.

Compositions and methods for modulating factor viii function

A FVIII and factor technology, applied in the fields of medicine and hematology, can solve problems such as immunogenicity

Pending Publication Date: 2021-08-24
THE CHILDRENS HOSPITAL OF PHILADELPHIA
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Also, whether protein or gene therapy is used, the immunogenicity of delivered or expressed FVIII can be problematic

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for modulating factor viii function
  • Compositions and methods for modulating factor viii function
  • Compositions and methods for modulating factor viii function

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0047] Preparation of Nucleic Acid Molecules and Polypeptides Encoding the Variants

[0048] Nucleic acid molecules encoding variants of the invention can be prepared by methods using recombinant DNA technology. The availability of nucleotide sequence information enables the preparation of isolated nucleic acid molecules of the invention by a variety of means. For example, nucleic acid sequences encoding variants can be isolated from suitable biological sources using standard protocols well known in the art.

[0049] Nucleic acids of the invention may be maintained as RNA or DNA in any convenient cloning vector. In a specific embodiment, clones are maintained in plasmid cloning / expression vectors such as pBluescript (Stratagene, La Jolla, CA), which are propagated in suitable E. coli host cells. Alternatively, the nucleic acid can be maintained in a vector suitable for expression in mammalian cells. In cases where post-translational modifications affect the function of th...

Embodiment 1

[0088] Non-viral vectors (naked DNA, 5 μg / mouse) expressing various human FVIII B domain variants and FVIII-SQ under the control of liver-specific promoters were injected via the tail vein route under hydrodynamic conditions (5 mice mice / variants). The variant B domains tested were: B1: SFSQNSRHPS (SEQ ID NO: 13); B2: SFSQNSRHPSTRQKQ (SEQ ID NO: 14); B3: SFSQNSRHPSTRQKQFNATT (SEQ ID NO: 15); B4: SFSQN (SEQ ID NO : 16); B5: SFSQNSRH (SEQ ID NO: 17); and B6: SFSQNSRHPSTRQKQFNATTIPENDIEKTD (SEQ ID NO: 18). After 24 hours, blood was collected and FVIII antigen levels were measured by ELISA using Affinity Biologicals Matched Pair Antibody Set Product#F8C-EIA. Such as figure 2 As shown, all human FVIII B domain variants of the present invention were expressed at higher levels than FVIII-SQ in hemophilia A mice.

Embodiment 2

[0090] Wild-type FVIII (659K) and its amino acid substitution variants were transiently expressed in BHK cells. The specific activity of expressed FVIII was determined by a one-stage aPTT assay in conditioned expression medium. Such as image 3 As shown, most FVIII variants showed increased specific activities compared to wild-type FVIII.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Factor VIII variants and methods of use thereof are disclosed.

Description

[0001] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 62 / 749,182, filed October 23, 2018. The aforementioned application is incorporated herein by reference. [0002] This invention was made with Government support under Grant No. R01 HL-137335-01A1 awarded by the National Institutes of Health. The government has certain rights in this invention. technical field [0003] The present invention relates to the fields of medicine and hematology. More specifically, the present invention provides novel Factor VIII variants and methods of using them to modulate the coagulation cascade in a patient in need thereof. Background technique [0004] Throughout this specification, several publications and patent documents are cited to describe the prior art to which the present invention pertains. Each of these references is hereby incorporated by reference in its entirety. [0005] Mutations in factor VIII (FVIII) can cause severe ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/14A61K38/16A61K38/37A61K38/54C12N15/63C07H21/04A61P7/04A61P7/08
CPCA61P7/04A61P7/08C07K14/755A61K38/00
Inventor 瓦尔德·R·阿鲁达本·萨梅尔森-琼斯
Owner THE CHILDRENS HOSPITAL OF PHILADELPHIA